세계의 줄기세포 시장 : 점유율 분석, 산업 동향 및 통계, 성장 동향 예측(2024-2029년)

The Global Stem Cell Market size is estimated at USD 12.40 billion in 2024, and is expected to reach USD 18.5 billion by 2029, growing at a CAGR of 10.20% during the forecast period (2024-2029).

Increased awareness about umbilical stem cells, growing demand for regenerative treatment options, and rising research and development initiatives to develop stem cell therapies are some of the major factors expected to drive the global market. In addition, increasing funding/grants for developing stem cell therapies is another factor projected to support the industry's expansion.

Increasing awareness about stem cells and their applications in advanced therapeutics like regenerative medicine and stem cell therapies is one of the major drivers of the market. For instance, according to an article published by Inflammation and Regeneration in December 2023, there is an increase in awareness levels of stem cells and their applications among people, and stem cells isolated from the umbilical cord are the effective off-the-shelve sources for cell and gene therapies in regenerative medicine and immunotherapies. Thus, such applications of stem cells in developing advanced therapeutics are key factors driving market growth.

In addition, the increase in the prevalence of chronic diseases and the growing implication of regenerative stem cell therapies in chronic diseases is another factor expected to support industry growth. For instance, according to a journal published by the American Heart Association, in March 2023, there were around 56.19 million heart failure cases globally. Thus, such an alarming increase in the burden of chronic diseases is expected to foster demand for innovative regenerative therapies for heart diseases, which, in turn, is expected to accelerate market growth.

The increased burden of chronic diseases has facilitated research efforts in regenerative stem cell therapy to develop promising therapeutics for such diseases. For instance, in December 2023, researchers from the Mayo Clinic and international collaborators demonstrated the effective role of stem cell-based regenerative therapy in advanced heart failure.

In January 2024, a stem cell therapy developed by UC Davis Health researchers for Crohn's disease showed promising effects in preclinical trials. Thus, increased research efforts in the stem cell therapy are projected to facilitate industry expansion during the forecast period.

Moreover, the increased funding/grants to develop promising stem cell-based therapeutics are further projected to support the market growth. For instance, in January 2024, CellVoyant received funding of GBP 7.6 million (USD 9.49 million) from Octopus Ventures to boost its efforts to develop advanced stem cell therapies for managing several life-threatening conditions. Similarly, in February 2023, the National Institutes of Health granted USD 2.5 million to the research team of Purdue University to accelerate their stem cell research. Thus, such increased funding activities are anticipated to cater to industry expansion.

Several strategic initiatives market players undertake are further projected to spur market growth. For instance, in April 2023, Gamida Cell Ltd, a cell therapy leader, announced US FDA approval of Omisirge, an allogeneic cell therapy for treating pediatric patients and adults with hematologic malignancies. This approval will likely increase stem cell transplant access and improve patient outcomes. Thus, such initiatives will likely foster market expansion during the forecast period.

Thus, owing to the abovementioned factors, such as the growing demand for regenerative medicine, increased burden of chronic diseases, the growing role of stem cells in the management of chronic disease, and increasing grants/funding for stem cell therapeutics are expected to offer significant growth for the market during the forecast period. However, expensive procedures, regulatory complications, and ethical and moral frameworks may hinder the market's growth.

Global Stem Cell Market Trends

The Oncology Disorders Segment is Expected to Exhibit the Fastest Growth Rate During the Forecast Period

The alarming increase in the burden of cancer globally, growing demand for innovative treatment options, the proven role of stem cell therapies in cancer treatment, and several strategic initiatives undertaken by industry participants are projected to augment segment uptake during the forecast period.

The increase in the burden of cancer and malignancies is expected to foster segment uptake over the coming years. For instance, according to the February 2024 updated data of Cancer Australia, the number of kidney cancer cases diagnosed ramped from 4,552 in 2022 to 4.600 people in 2023. Kidney cancer is the seventh most commonly diagnosed cancer in Australia, and it is estimated that one in 65 people will be diagnosed with the condition. Thus, the accelerating burden of cancer is expected to augment the demand for cell therapies like stem cell therapies for the effective management of cancer.

In addition, in recent years, stem cells have been used effectively in blood replenishment and immuno-reconstitution after cancer treatment. Also, these cells have gained remarkable traction across healthcare professionals for their role as a modality for delivering anti-tumor agents and their implication in tissue regeneration. A significant number of entities have reported positive outcomes of implementing this mode of tumor treatment. For instance, according to October 2023 data from the DVC Stem (Da Vinci Wellness Center), stem cells have shown promising outcomes in cancer, and approximately 87.5% of people realized improvement in their condition.

Similarly, in May 2023, a senior hematologist from Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, demonstrated stem cells' role in managing blood cancers and emphasized their roles in successful treatments. Thus, the evolving landscape of stem cell therapies in cancer and healthcare professionals' higher adoption of stem cell implants will likely cater to segment growth during the forecast period.

Several strategic initiatives market players undertake are further projected to augment segment growth during the forecast period. For instance, in October 2022, Bristol Myers Squibb (BMS) and Century Therapeutics formed a research collaboration to manufacture and commercialize four iPSC-derived (induced pluripotent stem cell) T-cell or natural killer cell programs for solid tumors and hematologic malignancies. Thus, such initiatives will likely foster segment growth during the forecast period.

Thus, owing to the abovementioned factors, such as the higher burden of cancer, growing demand for innovative therapeutics, and several strategic initiatives undertaken by the market players, segment growth is expected to propel during the forecast period.

North America is Expected to Hold a Significant Share in the Stem Cell Market During The Forecast Period

North America is projected to exhibit lucrative growth during the forecast period amid an increase in the prevalence of chronic diseases, growing research in stem cell therapies, the growing uptake of regenerative medicine in the region, and the region's supportive regulatory framework.

The increase in the burden of cancer in the United States is expected to fuel market growth. For instance, according to the American Cancer Society, the prevalence of mouth cancer is increasing in the country, and the country was about to report 15,490 mouth cancer cases in 2024 compared to 14,820 in 2023. Thus, the rising number of cancer cases is projected to fuel demand for advanced cancer therapies, which, in turn, will augment demand for stem cell therapies during the forecast period.

The rising emphasis on understanding stem cells' roles in cancer management has attracted researchers to develop cell-based cancer therapies. For instance, in January 2022, scientists from Cedars-Sinai demonstrated the role of stem cell therapies in cancer and their importance in improving cancer treatment.

Similarly, in December 2022, the City of Hope, a leader in stem cell medicine, and its Alpha Stem Cell Clinic received a USD 8 million grant from the California Institute of Regenerative Medicine to accelerate its role in regenerative medicine and cancer. Thus, such increased research efforts are likely to support regional market growth.

Also, a supportive regulatory framework coupled with rising demand for advanced therapeutics further fosters the regional market. For instance, in September 2023, the US Food and Drugs Administration approved motixafortide for use with filgrastim to prepare for a stem cell transplant. The approval is based on positive clinical trial results. In addition, in April 2023, the USFDA approved Omisirge, an allogeneic stem cell transplant therapy in the United States.

Thus, the factors mentioned above, such as North America's higher burden of chronic diseases, increasing research in stem cell therapeutics, and growing uptake of regenerative medicine in the region, are projected to accelerate regional market growth during the forecast period.

Global Stem Cell Industry Overview

The stem cell market is highly competitive and consists of several major players. In terms of market share, a few of the major players dominate the market. Major market players such as Thermo Fisher Scientific Inc., Sigma Aldrich (a subsidiary of Merck KGaA) BD, and Stem Cell Technologies are present. The major players' product advancements and improvements in stem cell technology are also increasing the competitive rivalry.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Demand For Stem Cell Banking
  • 4.2.2 Increasing Prevalence Of Chronic Disorders
  • 4.2.3 Ongoing Developments In Regenerative Medicine
  • 4.2.4 Rising Funds For Accelerating Stem Cell Research
• 4.3 Market Restraints
  • 4.3.1 Expensive Procedures
  • 4.3.2 Regulatory Complications and Ethical and Moral Framework
• 4.4 Industry Attractiveness- Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

• 5.1 By Product Type
  • 5.1.1 Adult Stem Cell
  • 5.1.2 Human Embryonic Cell
  • 5.1.3 Pluripotent Stem Cell
  • 5.1.4 Other Product Types
• 5.2 By Application
  • 5.2.1 Neurological Disorders
  • 5.2.2 Orthopedic Treatments
  • 5.2.3 Oncology Disorders
  • 5.2.4 Injuries and Wounds
  • 5.2.5 Cardiovascular Disorders
  • 5.2.6 Other Applications
• 5.3 By Treatment Type
  • 5.3.1 Allogeneic Stem Cell Therapy
  • 5.3.2 Autologic Stem Cell Therapy
  • 5.3.3 Syngeneic Stem Cell Therapy
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 United Kingdom
    • 5.4.2.2 Germany
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 ATCC
  • 6.1.2 Pluri Inc
  • 6.1.3 Thermo Fisher Scientific Inc.
  • 6.1.4 Takara Bio Inc
  • 6.1.5 Merck KGaA
  • 6.1.6 BD
  • 6.1.7 STEMCELL Technologies.
  • 6.1.8 AllCells LLC
  • 6.1.9 Miltenyi Biotec
  • 6.1.10 International Stem Cell Corporation
  • 6.1.11 ReNeuron Group PLC
  • 6.1.12 Bio-Techne

7 MARKET OPPORTUNITIES AND FUTURE TRENDS